Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01199523 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Effect of Oral Mirabegron on the Heart in Healthy Males and Females
A Phase 1 study, sponsored by Astellas Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 352
- Enrollment target
NCT01199523 is a Phase 1 study that has completed, run by Astellas Pharma. The registered enrollment target is 352 participants.
The verdict
NCT01199523, a Phase 1 study, has completed, sponsored by Astellas Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 352 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the effect of repeat oral dosing of mirabegron on ECG (electrocardiogram) measurements.
Interventions
- DRUG Placebo
- DRUG mirabegron
- DRUG moxifloxacin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 352 participants |
| Start Date | 2010-05 |
| Est. Completion | 2010-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01199523
The ClinicalTrials.gov registry entry for NCT01199523 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 352 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma, which has 165 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01199523 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01199523 about?
NCT01199523 is a clinical study titled "A Study to Evaluate the Effect of Oral Mirabegron on the Heart in Healthy Males and Females". The objective of this study is to evaluate the effect of repeat oral dosing of mirabegron on ECG (electrocardiogram) measurements.
What is the current status of trial NCT01199523?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 352 participants. The study started on 2010-05. Estimated completion is 2010-11.
What interventions are being tested in trial NCT01199523?
The interventions under investigation include: Placebo (DRUG), mirabegron (DRUG), moxifloxacin (DRUG).
Who is sponsoring clinical trial NCT01199523?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.